Black Diamond Therapeutics (BDTX) Accumulated Expenses (2018 - 2026)
Black Diamond Therapeutics' (BDTX) quarterly Accumulated Expenses came in at $11.6 million in Q1 2026, down 18.67% YoY from $14.2 million in Q1 2025, and down 23.67% on a QoQ basis from $15.2 million in Q4 2025.
Black Diamond Therapeutics (BDTX) Accumulated Expenses (2018 - 2026) Analysis & Trends
Black Diamond Therapeutics (BDTX) has 9 years of Accumulated Expenses data on file, last reported at $11.6 million in Q1 2026.
- Quarterly Accumulated Expenses fell 18.67% year-over-year to $11.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.6 million (down 18.67% YoY) and the FY2025 annual result came in at $15.2 million, down 8.54% from the prior year.
- Accumulated Expenses slipped to $11.6 million in Q1 2026, from $15.2 million in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $18.8 million in Q3 2024 to a low of $9.8 million in Q1 2023.
- A 5-year average of $15.1 million and a median of $15.4 million in 2022 frame the typical range for Accumulated Expenses.
- Annual changes were most pronounced in 2023 — Accumulated Expenses plunged 44.27% — and 2024, when it surged 59.96%.
- Tracing BDTX's Accumulated Expenses over 5 years: stood at $13.4 million in 2022, then rose by 29.42% to $17.3 million in 2023, then fell by 4.36% to $16.6 million in 2024, then dropped by 8.54% to $15.2 million in 2025, then dropped by 23.67% to $11.6 million in 2026.
- The last three Accumulated Expenses figures came in at $11.6 million (Q1 2026), $15.2 million (Q4 2025), and $14.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Black Diamond Therapeutics | 125.92 Mn | 15.42 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 14.44 Mn |
| Mar 31, 2026 | 11.57 Mn |
| Dec 31, 2025 | 15.15 Mn |
| Sep 30, 2025 | 14.57 Mn |
| Jun 30, 2025 | 16.03 Mn |
| Mar 31, 2025 | 14.22 Mn |
| Dec 31, 2024 | 16.57 Mn |
| Sep 30, 2024 | 18.83 Mn |
| Jun 30, 2024 | 17.68 Mn |
| Mar 31, 2024 | 15.68 Mn |
| Dec 31, 2023 | 17.32 Mn |
| Sep 30, 2023 | 14.37 Mn |
| Jun 30, 2023 | 11.16 Mn |
| Mar 31, 2023 | 9.80 Mn |
| Dec 31, 2022 | 13.38 Mn |
| Sep 30, 2022 | 15.38 Mn |
| Jun 30, 2022 | 17.48 Mn |
| Mar 31, 2022 | 17.59 Mn |
| Dec 31, 2021 | 19.54 Mn |
| Sep 30, 2021 | 21.50 Mn |